Q3 EPS Estimates for Atossa Genetics Increased by Analyst

Atossa Genetics Inc. (NASDAQ:ATOS) – Investment analysts at Zacks Research increased their Q3 2026 earnings per share estimates for Atossa Genetics in a research note issued on Friday, August 14th. Zacks Research analyst D. Bautz now anticipates that the company will post earnings per share of ($0.74) for the quarter, up from their previous estimate of ($1.02). The consensus estimate for Atossa Genetics’ current full-year earnings is ($4.30) per share. Zacks Research also issued estimates for Atossa Genetics’ Q4 2026 earnings at ($0.73) EPS, FY2026 earnings at ($3.49) EPS, FY2027 earnings at ($2.73) EPS and FY2028 earnings at ($2.38) EPS.

Several other equities analysts have also recently issued reports on the stock. Rodman & Renshaw assumed coverage on shares of Atossa Genetics in a research note on Tuesday, July 7th. They issued a “buy” rating and a $12.00 target price for the company. Weiss Ratings lowered shares of Atossa Genetics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, June 11th. Finally, Wall Street Zen raised shares of Atossa Genetics from a “strong sell” rating to a “sell” rating in a report on Saturday, August 15th. Three equities research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average price target of $20.33.

Atossa Genetics Price Performance

Shares of NASDAQ ATOS opened at $2.64 on Thursday. The stock has a market capitalization of $26.34 million, a price-to-earnings ratio of -0.85 and a beta of 1.29. Atossa Genetics has a 12 month low of $1.70 and a 12 month high of $19.35. The firm’s 50 day simple moving average is $2.28 and its 200-day simple moving average is $4.08.

Atossa Genetics (NASDAQ:ATOS) last announced its quarterly earnings results on Friday, August 7th. The company reported ($0.95) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.02) by $0.07.

Institutional Trading of Atossa Genetics

Institutional investors have recently bought and sold shares of the business. Geode Capital Management LLC increased its position in shares of Atossa Genetics by 0.7% in the fourth quarter. Geode Capital Management LLC now owns 1,371,909 shares of the company’s stock valued at $810,000 after buying an additional 9,627 shares in the last quarter. Hudson Bay Capital Management LP acquired a new position in shares of Atossa Genetics during the 2nd quarter worth approximately $26,000. JPMorgan Chase & Co. lifted its position in shares of Atossa Genetics by 1,294.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 38,215 shares of the company’s stock valued at $33,000 after buying an additional 35,474 shares in the last quarter. Bank of America Corp DE lifted its position in shares of Atossa Genetics by 55.7% during the 2nd quarter. Bank of America Corp DE now owns 99,601 shares of the company’s stock valued at $83,000 after buying an additional 35,629 shares in the last quarter. Finally, &PARTNERS acquired a new stake in Atossa Genetics in the 4th quarter valued at $25,000. 12.74% of the stock is owned by institutional investors and hedge funds.

Atossa Genetics Company Profile

Atossa Genetics, Inc is a clinical-stage biotechnology company based in Seattle, Washington, focused on developing therapeutics and diagnostic products for breast cancer and other breast-related conditions. The company’s mission centers on delivering targeted, minimally invasive solutions that address early detection, treatment, and prevention in women at risk for or diagnosed with breast malignancies.

The company’s pipeline includes Z-Endoxifen, an oral formulation of endoxifen designed to treat and prevent estrogen receptor–positive breast cancers, particularly in patients with ductal carcinoma in situ or those at high risk of recurrence.